CME/CE

Faculty: J.A. Randy Englert, MD, FACC Faculty: Matthew Malachowski, Pharm. D., MHA This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL...

Faculty: J.A. Randy Englert, MD, FACC Faculty: Matthew Malachowski, Pharm. D., MHA This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL...

Faculty: J.A. Randy Englert, MD, FACC Faculty: Matthew Malachowski, Pharm. D., MHA This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL...

Faculty: J.A. Randy Englert, MD, FACC Faculty: Matthew Malachowski, Pharm. D., MHA This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL...

Faculty: J.A. Randy Englert, MD, FACC This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustain...

Faculty: Erica L. Mayer, MD, MPH Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optimizing...

Faculty: Aditya Bardia, MD, MPH, FASCO Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optim...

Faculty: Aditya Bardia, MD, MPH, FASCO Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optim...

Faculty: Maria Fleseriu, MD, FACE Faculty: Shlomo Melmed, MBChB Faculty: Elise M. Brett, MD, FACE This broadcast replay from AACE 2026 features an interactive, case-based Q-Challenge format focused on acromegaly. Participants engage with clinical scenarios designed to assess and reinforce diagnostic evaluation and treatment decision-making. The activity highlights key considerations in identifying...

Host: Brett Bade, MD Guest: Michael Gieske, MD This episode focuses on improving lung cancer screening and early detection by helping primary care providers recognize eligible and high-risk patients, apply current screening guidelines, and engage patients in clear shared decision-making conversations. Speakers will explore why many patients who qualify for low-dose CT scan screening are still not...

Faculty: Michael Dolinger, MD, MBA Faculty: David T. Rubin, MD This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-...

Faculty: Michael Dolinger, MD, MBA Faculty: David T. Rubin, MD This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-...

Faculty: Michael Dolinger, MD, MBA Faculty: David T. Rubin, MD This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-...

Faculty: Michael Dolinger, MD, MBA Faculty: Florence Odufalu, MD This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective ant...

Faculty: Ugo Iroku, MD, MHS Faculty: Michael Dolinger, MD, MBA This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-...

Faculty: Florence Odufalu, MD Faculty: Ugo Iroku, MD, MHS Faculty: Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover convention...

Faculty: Robert D. Suh, MD Faculty: Ashwin Basavaraj, MD Faculty: Mary Salvatore, MD, MBA Bronchiectasis is a chronic, progressive respiratory disease that is characterized by accelerated lung function decline and impaired quality of life, yet it remains substantially under recognized and underdiagnosed in routine practice. High-resolution computed tomography is the cornerstone of diagnosis, but e...

Faculty: Florence Odufalu, MD Faculty: Ugo Iroku, MD, MHS This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-integ...

Faculty: Kathleen N. Moore, MD, MS Dr. Kathleen Moore reviews the clinical significance of HER2 expression across diverse solid tumors and its role in guiding treatment decisions. She outlines HER2 testing methodologies, including immunohistochemistry (IHC), to identify patients with advanced solid tumors who may benefit from HER2-targeted antibody–drug conjugates (ADCs). Dr. Moore summarizes key...

Faculty: Jean Hoffman-Censits, MD This 15-minute online CME activity reviews the clinical implications of the updated NCCN Guidelines for advanced urothelial carcinoma (aUC), with a focus on evolving first-line and subsequent treatment strategies. The program highlights the shift away from cisplatin eligibility as the primary determinant of frontline therapy selection and examines key clinical tri...

Faculty: Adam J. Luginbuhl, MD Faculty: Jennifer Johnson, MD, PhD This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, r...

Faculty: Jennifer Johnson, MD, PhD This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitne...

Faculty: Jennifer Johnson, MD, PhD This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitne...

Faculty: Adam J. Luginbuhl, MD This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness f...

Faculty: Adam J. Luginbuhl, MD This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness f...